Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Kamat on the Process of Meeting BCG Needs in Bladder Cancer

March 23rd 2021

Ashish M. Kamat, MD, discusses the process of meeting the needs for TICE Bacillus Calmette–Guérin in the treatment of patients with bladder cancer.

Checkpoint Inhibition Makes Way Into NCCN Urothelial Cancer Guidelines in Maintenance and Second-Line Setting

March 20th 2021

Immunotherapy is now incorporated into National Comprehensive Cancer Network guidelines as maintenance therapy and in a sequencing strategy for the treatment of patients with metastatic urothelial carcinoma and in the setting of superficial UC-carcinoma in situ with prior intravesical therapy.

Dr. Choueiri on the CheckMate-9ER Exploratory Analysis in Advanced RCC

March 18th 2021

Toni K. Choueiri, MD, discusses results from an exploratory analysis of the phase 3 CheckMate-9ER trial in patients with advanced renal cell carcinoma.

Dr. Motzer on the Efficacy of Cabozantinib in RCC

March 18th 2021

Robert J. Motzer, MD, discusses the efficacy of cabozantinib in patients with renal cell carcinoma.

Dr. Atkins on the FDA Approval of Tivozanib in Relapsed/Refractory Advanced RCC

March 16th 2021

Michael B. Atkins, MD, discusses the FDA approval of tivozanib in relapsed/refractory advanced renal cell carcinoma.

FDA Grants Priority Review to Belzutifan for VHL Disease–Associated RCC

March 16th 2021

The FDA has granted priority review to the new drug application for the HIF-2α inhibitor belzutifan for the potential treatment of patients with von Hippel-Lindau–associated renal cell carcinoma that does not require immediate surgery.

Dr. Devitt on the Impact of Withdrawn Immunotherapy Agents in Bladder Cancer

March 15th 2021

Michael Devitt, MD, discusses the recent withdrawals of immunotherapy agents used to treat patients with bladder cancer.

Frontline mRCC Paradigm Crowds Among Immune-Based Treatment Options

March 13th 2021

The emergence of multiple combination regimens with immunotherapy and TKIs has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma; however, without head-to-head comparative data, treatment selection has become individualized based on available patient characteristics.

Novel Targeted and Immunotherapeutic Agents Reshape Metastatic Urothelial Cancer Landscape

March 12th 2021

Treatment options for patients with metastatic urothelial cancer have rapidly expanded as FDA approvals of immunotherapeutics push the boundaries of a once stagnant treatment landscape. Combination regimens and the addition of targeted approaches, further demonstrate progress in areas that have been tough to crack.

FDA Will Reassess 6 Immunotherapy Accelerated Approvals

March 12th 2021

Six indications for immune checkpoint inhibitors granted under the FDA’s accelerated approval process that later failed confirmatory clinical trials are being reassessed as the agency continues an industry-wide evaluation of the pathway.

FDA Approves Tivozanib for Relapsed/Refractory Advanced RCC

March 10th 2021

The FDA has approved tivozanib (Fotivda) for the treatment of adult patients with relapsed/refractory advanced renal cell carcinoma following 2 or more prior systemic therapies.

Roche Withdraws Atezolizumab Prior-Platinum Treated Metastatic Bladder Cancer Indication in the United States

March 8th 2021

Roche has withdrawn atezolizumab from the US market for the treatment of patients with metastatic urothelial carcinoma who had previously received platinum-based therapy.

NEJM Data Underscore Frontline Nivolumab/Cabozantinib Benefit Over Sunitinib in Advanced RCC

March 5th 2021

The combination of nivolumab and cabozantinib showcased significant benefit in terms of progression-free survival, overall survival, and responses vs sunitinib in the frontline treatment of patients with advanced renal cell carcinoma, as was underscored in data from the phase 3 CheckMate-9ER trial.

Dr. Zhang on Emerging Biomarkers of Response to Immunotherapy in RCC

March 1st 2021

Tian Zhang, MD, discusses emerging biomarkers that are helping to guide treatment for patients with renal cell carcinoma.

Cabozantinib/Nivolumab Approaches EU Approval for Frontline Advanced RCC

February 26th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of cabozantinib plus nivolumab for use as a frontline treatment in patients with advanced renal cell carcinoma.

Ilixadencel/Sunitinib Combo Showcases Promising Survival Benefit in mRCC

February 24th 2021

February 24, 2021—The off-the-shelf immune primer ilixadencel in combination with sunitinib showcased an encouraging, clinically meaningful survival benefit when used in the first-line treatment of newly diagnosed patients with metastatic renal cell carcinoma.

Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC and Ovarian Cancer

February 23rd 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

Biomarker-Guided Therapies, Novel Combos Take Center Stage in Urothelial Carcinoma

February 23rd 2021

Jason Zhu, MD, discusses several approaches under exploration in the treatment of patients with previously treated, locally advanced, or metastatic urothelial carcinoma.

Investigators Aim Novel T-Cell Therapy at Solid Tumor Target

February 23rd 2021

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Nichols on Navigating the Nuances of von Hippel-Lindau Disease

February 22nd 2021

In our exclusive interview, Dr. Nichols discusses von Hippel-Lindau disease in great detail, how she currently approaches treatment with these patients, and the importance of routine surveillance in this population.